User:Y.s.a.law/DPT vaccine

Article Draft
Vaccination rates

In 2016, the CDC reported that 80.4% of children in the US have received 4 or more DTaP vaccinations by 24 months. Vaccination rates for children aged 13-17 with one or more TDaP shots is 90.2%. Only 43.6% of adults (older than 18) have received a TDaP shot in the last 10 years.

Tdap[edit]
In pregnant persons, research suggests that Tdap administration may be associated with an increased risk of chorioamnionitis, a placental infection. Increased incidence of fever is also noted in pregnant persons. Despite the observed increase in incidence of chorioamnionitis in pregnant persons following Tdap administration, there has been no observed increase in the incidence of preterm birth, for which chorioamnionitis is a risk factor. Research has not discerned an association between Tdap administration during pregnancy and other serious pregnancy complications such as neonatal death and stillbirth. An association between Tdap administration during pregnancy and pregnancy-related hypertensive disorders (such as pre-eclampsia and eclampsia) has not been identified.

United States[edit]
The standard immunization regimen for children within the United States is five doses of DTaP between the ages of two months and fifteen years. To be considered to be fully vaccinated, the Center for Disease Control and Prevention (CDC) typically requires five doses of TdaP. The CDC recommends that children receive their first dose at two months, the second dose at four months, the third dose at six months, the fourth dose between 15 and 18 months, and the fifth dose between 4–6 years. If the fourth dose of the DTaP immunization regimen falls on or subsequent to the recipient's fourth birthday, the CDC states that only four doses are required to be fully vaccinated. In the instance that an individual under 18 has not received the DTaP vaccine, individuals should be vaccinated on the schedule in accordance with the vaccination "catch up schedule" provided by the CDC.

In pregnancy[edit]
For women not previously vaccinated with Tdap, if Tdap is not administered during pregnancy, it should be administered immediately postpartum. Postpartum administration of TDaP is not equivalent to administration of the vaccination during pregnancy. Because the vaccine is administered postpartum, the birthing parent is unable to develop antibodies that can be transferred to the infant in utero, consequently, leaving the infant vulnerable to the diseases preventable by the Tdap Vaccine. Postpartum administration of the TdaP vaccine to the birthing parent seeks to reduce the likelihood that the birthing parent will contract disease that can be subsequently passed on the infant, albeit there will still be a two week period prior to the protective effects of the vaccine setting in. Postpartum administration is an extension of the concept of "cocooning," a term that refers to the full vaccination of all individuals that may come into direct contact with the infant. Cocooning, like postpartum Tdap aministration, is not recommended by the CDC. Cocooning depends on ensuring full vaccination of all individuals that the the infant may come into contact with, and there may be financial, administrative or personal barriers that preclude full and timely vaccination of all individuals within the "cocoon."